Core Insights - UCB, a Belgian pharmaceutical company, announced a $2 billion investment to build a drug manufacturing plant in suburban Atlanta, aiming to enhance its presence in the U.S. market [1][2] - The new facility is expected to create approximately 330 jobs and is part of UCB's strategy to meet increasing demand for its products [1][2] Company Growth and Financials - UCB's revenues are projected to grow by 26% to nearly $9 billion (7.74 billion euros) in 2025, with profits expected to rise by 46% to $1.81 billion (1.56 billion euros) [2] - The company has a workforce of about 2,000 employees in the U.S. and plans to hire more U.S.-based contract manufacturers [2] Product Focus - UCB has a history of developing antihistamines like Zyrtec and Xyzal, and is currently focused on drugs for neurological and autoimmune diseases, with Bimzelx being a key product for treating autoimmune disorders [3] Location and Strategic Advantages - The new plant will be situated in a research park in Gwinnett County, Georgia, which aims to become a hub for biomedical research, similar to North Carolina's Research Triangle Park [4] - The proximity to Georgia Tech and the University of Georgia is expected to foster collaboration in biomedical research and manufacturing [4] Investment and Incentives - The construction of the plant is anticipated to take six to seven years, with Gwinnett County committing $174 million in incentives, including property tax breaks and infrastructure improvements [5] - UCB may also qualify for additional state income tax credits and sales tax waivers on equipment purchases [5]

Core Viewpoint - XORTX Therapeutics Inc. has received shareholder approval to consolidate its common shares to comply with NASDAQ listing requirements, specifically to ensure shares trade above $1.00 by April 13, 2026 [1][2] Share Consolidation Details - The consolidation will be on a basis of up to five pre-consolidation common shares for every one post-consolidation common share [1] - Currently, there are 6,962,218 common shares issued and outstanding, which will reduce to approximately 1,392,443 shares post-consolidation, depending on the handling of fractional shares [3] - No fractional common shares will be issued; they will either be canceled or rounded up to the nearest whole number [3] Trading and Shareholder Instructions - If approved by the TSX Venture Exchange, trading on a post-consolidation basis will commence on a date to be determined [4] - Registered shareholders will receive a letter of transmittal with instructions for exchanging their share certificates, while beneficial shareholders will not need to take action [4] Company Overview - XORTX is focused on developing therapies for gout and progressive kidney disease, with three advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [5] - The company is also developing XRx-225 for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [5]

Core Insights - Alnylam has marked a significant milestone with the one-year anniversary of AMVUTTRA's approval in the U.S. for patients with ATTR cardiomyopathy, indicating a new era of growth for the company [2] - The introduction of ONPATTRO in 2018 established a new class of RNAi therapeutics, providing transformative options for patients with hereditary ATTR amyloidosis with polyneuropathy [2][3] - The company is experiencing strong adoption of AMVUTTRA, particularly in the ATTR cardiomyopathy population, which is more prevalent than hereditary ATTR polyneuropathy [3] Company Strategy - Alnylam is investing in advanced capabilities aimed at enabling earlier diagnosis, better coordinated care, and improved long-term outcomes for patients [4] - The strategic focus is to lead with scientific innovation, target untreated patients or those progressing on stabilizers, and deliver a durable impact [4] - The company is advancing its next-generation TTR therapy, nucresiran, which has the potential to enhance treatment outcomes further [3]

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by a specified deadline [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Aquestive and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until May 4, 2026, to request appointment as Lead Plaintiff if they purchased or acquired Aquestive securities during the Class Period [2]. Group 2: Company Performance and Regulatory Issues - On January 9, 2026, Aquestive received a letter from the U.S. FDA identifying deficiencies that delayed discussions on labeling for Anaphylm (Dibutepinephrine) sublingual film, which had a New Drug Application submitted [4]. - Following the FDA's letter, Aquestive's stock price fell by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4] Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5] - It is claimed that the defendants made overly positive statements while concealing material adverse facts about the drug's efficacy and the study protocols, leading to inflated stock prices for Ultragenyx [6]

Table of Contents As filed with the U.S. Securities and Exchange Commission on March 24, 2026. Registration No. 333-290086 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTIMI HEALTH CORP. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) (State or other jurisdiction of incorporation or organization) British Columbia 2834 Not Applic ...

Core Insights - Biomea Fusion, Inc. has made significant progress in clinical trials for its lead asset, icovamenib, targeting type 2 diabetes, with promising 52-week clinical data reported [2][5] - The company has initiated two Phase II trials for icovamenib and advanced its next-generation oral GLP-1 receptor agonist, BMF-650, into a Phase I study [2][4] - Financial results for the year ended December 31, 2025, show a net loss of $61.8 million, a reduction from $138.4 million in 2024, indicating improved financial management [7][14] Clinical Development - Icovamenib demonstrated a persistent 1.2% mean reduction in HbA1c in patients with type 2 diabetes, maintained through Week 52 after a 12-week treatment [5] - Two Phase II trials, COVALENT-211 and COVALENT-212, have been initiated, with primary endpoint data expected in the fourth quarter of 2026 [4][11] - BMF-650 is undergoing a Phase I trial, with initial 28-day weight reduction data anticipated in the second quarter of 2026 [4][11] Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and restricted cash of $56.2 million, a slight decrease from $58.6 million in 2024 [11][17] - Research and Development (R&D) expenses decreased to $62.0 million in 2025 from $118.1 million in 2024, primarily due to a strategic realignment [11][14] - General and Administrative (G&A) expenses also decreased to $19.3 million in 2025 from $26.0 million in 2024, reflecting cost-saving measures [11][14] Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, addressing a significant global health challenge [8] - The company's mission is to deliver transformative treatments for patients with diabetes, obesity, and related conditions [8]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Aldeyra Therapeutics, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the FDA's announcement, Aldeyra's stock price fell by $2.99 per share, representing a 70.7% decline, closing at $1.24 per share on March 17, 2026 [3]. Group 2: Legal Actions - Investors who purchased Aldeyra securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Rezolute provided updates on its Phase 3 sunRIZE trial for ersodetug, focusing on congenital hyperinsulinism treatment, following a meeting with the FDA on March 17 [1] Efficacy and Regulatory Insights - The primary endpoint of the sunRIZE trial was not statistically significant, but there were clinically meaningful improvements in hypoglycemia events as measured by continuous glucose monitoring [2] - The FDA highlighted the importance of well-controlled studies due to challenges posed by behavioral factors in clinical trials [2] - Rezolute is expected to submit further study reports for independent evaluation, which may lead to a marketing application for ersodetug later this year [3][4] Future Steps and Expectations - The FDA encouraged Rezolute to submit study reports and analysis datasets for independent evaluation, which will determine if sufficient evidence exists to support a marketing application for sunRIZE [4][5] - An update on the program is anticipated in the second half of 2026 [5] Technical Analysis - The stock is trading 13.9% below its 20-day simple moving average (SMA) and 48.5% below its 100-day SMA, indicating a bearish trend [6] - Shares have decreased by 15.84% over the past 12 months and are closer to their 52-week lows [6] - The RSI is at 35.46, indicating neutral territory, while the MACD shows bearish pressure with a value of -0.2377 [6][7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $10.67, with recent analyst actions indicating mixed sentiments [8] - Rezolute shares were up 7.29% at $2.58 at the time of publication [8] - Key resistance is at $3.00 and key support is at $2.00, with various analysts adjusting their price targets [8]

Core Insights - ImmunityBio's shares increased by 11% following the approval of its lead drug, Anktiva, by Macau's regulatory body for treating specific bladder cancer patients [1][7] - Anktiva, in combination with Bacillus Calmette-Guérin (BCG), is approved for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) [1][7] Regulatory Approval - The approval was based on the phase II/III QUILT-3.032 study, which demonstrated a complete response rate of 71% and a median duration of response of 26.6 months [2] - Anktiva is now approved in 34 countries and territories, marking its first regulatory authorization in Asia [3] Financial Performance - ImmunityBio reported revenues of $113 million in 2025, reflecting a year-over-year increase of approximately 700% [8] - The company's stock has surged by 282.1% over the past six months, significantly outperforming the industry average increase of 14.7% [6] Development Activities - ImmunityBio is pursuing additional label expansion opportunities for Anktiva, including a recent resubmission to the FDA for BCG-unresponsive NMIBC with papillary disease [8] - The company is also advancing a randomized study for Anktiva plus BCG in BCG-naïve NMIBC patients, targeting a regulatory filing in the near term [9] Broader Applications - Beyond bladder cancer, ImmunityBio is exploring Anktiva in combination with standard therapies and CAR-NK approaches for various difficult-to-treat cancers, including non-small cell lung cancer (NSCLC) and pancreatic cancer [10] - The therapy received its first regulatory approval for NSCLC in Saudi Arabia and discussions with the FDA for further label expansion are planned [10]